1. Cummings, J.L. et al. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease. Alzheimer’s Research & Therapy 8, 4 (2016). Link
    2. Liu, E. et al. Amyloid-beta 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology 85, 692-700 (2015). Link
    3. Lin, P.J., Yang, Z., Fillit, H.M., Cohen, J.T. & Neumann, P.J. Unintended benefits: the potential economic impact of addressing risk factors to prevent Alzheimer’s disease. Health Affairs 33, 547-554 (2014).  Link
    4. Michaelson, D.M. APOE epsilon4: the most prevalent yet understudied risk factor for Alzheimer’s disease. Alzheimer’s & Dementia: the Journal of the Alzheimer’s Association 10, 861-868 (2014). Link
    5. Farrer, L.A. et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta-Analysis Consortium. Jama 278, 1349-1356 (1997).  Link
    6. Corder, E.H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921-923 (1993).  Link
    7. Calero O, García-Albert L, Rodríguez-Martín A, Veiga S, Calero M. A fast and cost-effective method for apolipoprotein E isotyping as an alternative to APOE genotyping for patient screening and stratification. Sci Rep. 2018 Apr 13;8(1):5969. doi: 10.1038/s41598-018-24320-3. PubMed PMID: 29654261.   Link

If you have any questions or comments,  we will be pleased to attend you

If you have any questions or comments,  
we will be pleased to attend you

Avda. Francisco Vallés, 8
47151 Boecillo (Valladolid) - Spain

+34 983 54 98 96